Barron Signs Off With Notes On GSK Culture Change, Tease On RSV Vaccine Results
Transformation Not Yet Complete, Says Departing R&D Chief
Hal Barron is leaving just as GSK’s M&A firepower grows following the Haleon spin-out, but sounded a confident note about its potential blockbuster RSV vaccine candidate.
You may also be interested in...
J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
GSK’s New Research Chief Begins Leadership With Expanded Genomics/AI Alliance
GSK’s new chief scientific officer Tony Wood is building on the precision medicine approach by partnering with Tempus to accelerate cancer drug trials and improve the firm’s R&D productivity.
Consumer Spin-Off Finally Achieved, GSK Will Weigh More M&A
GSK is entering a new era, and CEO Emma Walmsley looks likely to use new finances for more targeted M&A.